News

Dr. Tim Pluard, medical director of Saint Luke’s Koontz Center for Advanced Breast Cancer and of Saint Luke’s Cancer Institute, talks about innovative treatment options for breast cancer and clinical trials offered at Saint Luke’s.

This year, Michelle almost skipped her preventive screening, but instead of skipping, she chose to get her first 3D mammogram. And like many women, she wasn’t aware that it was now covered by insurance.

We’re talking about how younger women and men can monitor for breast cancer and recent updates in screening guidelines.

A man from Columbia, Missouri, got a new heart and a second chance at life, marking the 1,000th heart transplant at Saint Luke's Mid America Heart Institute.

This week during Breast Cancer Awareness Month, we’re talking about metastatic breast cancer and Saint Luke’s Koontz Center—the region’s only center dedicated and designed specifically for these patients.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.

Dr. Mikhail Kosiborod presented on the benefits of a cardiometabolic center of excellence for patients with cardiometabolic diseases at the ADA conference in San Diego.